Tracking Alzheimer’s biomarkers and quality of life over time
Integrative analysis for patient-centered outcomes and time-to-event data in Alzheimer's disease
This project develops new ways to use biomarkers, genetics, and health records to predict Alzheimer’s risk and how it may affect quality of life for people before symptoms appear.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11457079 on NIH RePORTER |
What this research studies
This work will create statistical tools that map how individual biomarkers change years before symptoms of Alzheimer’s show up. The team will combine those biomarker paths with genetic data and time-varying information from electronic health records to build personalized risk profiles. Methods will be designed to handle sparse or irregular medical tests and to link biomarker changes to disease onset and patient-reported quality of life. The goal is to produce dynamic predictions that could guide earlier, more tailored monitoring and care.
Who could benefit from this research
Good fit: Ideal candidates are people at risk for Alzheimer’s or in very early/asymptomatic stages who have longitudinal biomarker tests, genetic data, or comprehensive electronic health records available.
Not a fit: People without repeated biomarker measurements, genetic information, or accessible longitudinal health records are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, the project could enable earlier, personalized predictions of Alzheimer’s risk and inform care planning to preserve quality of life.
How similar studies have performed: Previous studies have linked biomarkers and health records to Alzheimer’s risk, but this project’s focus on individualized biomarker trajectories combined with quality-of-life predictions is a newer, less-tested approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Zhao, Yize — Yale University
- Study coordinator: Zhao, Yize
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.